

# Facet Joint Injections - Single Service

Clinical Guidelines for Medical Necessity Review

Version:

**Effective Date:** September 20, 2024

# **Important Notices**

#### **Notices & Disclaimers:**

GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.

Cohere Health, Inc. ("Cohere") has published these clinical guidelines to determine medical necessity of services (the "Guidelines") for informational purposes only, and solely for use by Cohere's authorized "End Users". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2024 Cohere Health, Inc. All Rights Reserved.

#### Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

#### **Guideline Information:**

Specialty Area: Diseases & Disorders of the Musculoskeletal System (M00-M99)

Guideline Name: Facet Joint Injections (Single Service)

Literature review current through: 9/20/2024

Document last updated: 9/20/2024

**Type:** [X] Adult (18+ yo) | [X] Pediatric (0-17 yo)

### **Table of Contents**

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	4
Service: Facet Injections	4
General Guidelines	4
Medical Necessity Criteria	4
Indications	4
Level of Care Criteria	6
Procedure Codes (CPT/HCPCS)	7
Medical Evidence	15
References	17
Clinical Guideline Revision History/Information	19

# **Medical Necessity Criteria**

#### Service: Facet Injections

#### **General Guidelines**

- **Units, Frequency, & Duration:** Conflicting evidence and recommendations from different work groups on the utility of facet joint diagnostic injections.
- **Criteria for Subsequent Requests:** For second injections, the previous injection must result in greater than 50% relief of symptoms. If the patient has had greater than or equal to 2 injections, the previous injection must result in a 50% improvement of symptoms for 3 months. 1-3
- Recommended Clinical Approach: There is insufficient evidence to make a recommendation for or against the diagnostic utility of zygapophyseal/facet joint injections.
- Exclusions: None.

#### **Medical Necessity Criteria**

#### **Indications**

- → Facet joint injections may be appropriate if ANY of the following is TRUE:
  - ◆ The injection is an initial diagnostic injection, and ALL of the following are TRUE: 1.3-4
    - Failure of conservative management for greater than 3 months, including ALL of the following:
      - Oral steroids, anti-inflammatory medications, or analgesics if not contraindicated; AND
      - Physical therapy; AND
      - Documented activity/lifestyle modification; AND
      - o **ANY** of the following:
        - Corticosteroid injection if medically appropriate; OR
        - Corticosteroid injection is contraindicated; OR
    - The patient has undergone advanced imaging which reveals ANY of the following:

- Facet arthritis at the level requested; OR
- Lumbar spondylosis (arthritis); AND
- Other sources of pain have been ruled out with clinical assessment and/or radiologic imaging; AND
- Frequency limitation indicated by ALL of the following:
  - No more than I spinal region (cervical, thoracic, or lumbar) is being injected per session; AND
  - No more than 1 to 2 levels (either unilateral or bilateral) is being injected per spine region per session; OR
- ◆ The injection is a second diagnostic (confirmatory) injection and ALL of the following are TRUE:<sup>5</sup>
  - The first injection was successful at greater than or equal to 80% pain relief; AND
  - The injection is being performed at the same level as the initial diagnostic injection; AND
  - The injection is no sooner than I week after the initial diagnostic injection; AND
  - Frequency limitation indicated by ALL of the following:
    - No more than I spinal region (cervical, thoracic, or lumbar) is being injected per session; AND
    - No more than 1 to 2 levels (either unilateral or bilateral) is being injected per spine region per session; OR
- ◆ The injection is a therapeutic facet injection, and ANY of the following are TRUE:<sup>5</sup>
  - The injection is an initial therapeutic facet injection, and ALL of the following are TRUE:
    - The patient still meets the initial criteria for the diagnostic facet injections; AND
    - The patient has had 2 diagnostic facet joint injections at the same level; AND
    - The 2 diagnostic facet joint injections provided greater than or equal to 80% pain relief; OR
  - The injection is a subsequent therapeutic facet injection, and ALL of the following are TRUE:
    - The patient still meets the initial criteria for the diagnostic facet injections; AND

- Each prior therapeutic facet injection has provided greater than or equal to 50% pain relief for greater than or equal to 3 months; AND
- Each prior therapeutic injection has provided greater than or equal to 50% improvement in activities of daily living (ADLs); AND
- The patient has not had greater than 3 therapeutic injections at that level per year; AND
- Documentation of why the patient is not a candidate for radiofrequency ablation (RFA); OR
- The injection is being performed to treat pain related to a facet joint synovial cyst confirmed by MRI imaging with concordant pain at that level<sup>6</sup>; OR
- Frequency limitation indicated by ALL of the following:
  - No more than I spinal region (cervical, thoracic, or lumbar) is being injected per session; AND
  - No more than 1 to 2 levels (either unilateral or bilateral) is being injected per spine region per session.

#### **Non-Indications**

- → Facet joint injections are not considered appropriate if ANY of the following is TRUE:
  - ◆ Known non-facet source of pain; OR
  - Systemic infection; OR
  - ◆ Local infection at the procedure site; **OR**
  - ◆ Coagulopathy or recent use of blood thinning agents<sup>3</sup>; **OR**
  - Facet joint injection performed without CT fluoroscopic guidance;
     OR
  - Diagnostic injection at the same level as a previously successful RFA; OR
  - Multiple blocks performed on the same day as a facet injection;
     OR
  - Injections of biologics or other substances that are non-FDA approved for facet joint injections.

#### **Level of Care Criteria**

Outpatient

### Procedure Codes (CPT/HCPCS)

Procedure Codes (C	
CPT/HCPCS Code	Code Description
64490	Injection of diagnostic agent into nerve of single cervical paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of single cervical paravertebral facet joint using imaging guidance; Injection of diagnostic agent into nerve of single thoracic paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of single thoracic paravertebral facet joint using imaging guidance; Injection of diagnostic agent into single cervical paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into single cervical paravertebral facet joint using imaging guidance; Injection of diagnostic agent into single thoracic paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into single thoracic paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into single thoracic paravertebral facet joint using imaging guidance; Injection of therapeutic agent into nerve of single cervical paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into nerve of single thoracic paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into single cervical paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into single thoracic paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into single thoracic paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into single thoracic paravertebral facet joint using computed tomography (CT) guidance.
64491	Injection of diagnostic agent into nerve of second cervical paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of second

cervical paravertebral facet joint using imaging guidance; Injection of diagnostic agent into nerve of second thoracic paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of second thoracic paravertebral facet joint using imaging guidance; Injection of diagnostic agent into second cervical paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into second cervical paravertebral facet joint using imaging guidance; Injection of diagnostic agent into second thoracic paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into second thoracic paravertebral facet joint using imaging guidance; Injection of therapeutic agent into nerve of second cervical paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into nerve of second thoracic paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into second cervical paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into second thoracic paravertebral facet joint using computed tomography (CT) guidance. 64492 Injection of diagnostic agent into nerve of third and any additional cervical paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of third and any additional cervical paravertebral facet joint using imaging guidance; Injection of diagnostic agent into nerve of third and any additional thoracic paravertebral facet joint using fluoroscopic guidance;

Injection of diagnostic agent into nerve of third and any additional thoracic paravertebral facet joint using imaging guidance; Injection of diagnostic agent into third and any additional cervical paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into third and any additional cervical paravertebral facet joint using imaging guidance; Injection of diagnostic agent into third and any additional thoracic paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into third and any additional thoracic paravertebral facet joint using imaging guidance; Injection of therapeutic agent into nerve of third and any additional cervical paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into nerve of third and any additional thoracic paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into third and any additional cervical paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into third and any additional thoracic paravertebral facet joint using computed tomography (CT) guidance. 64493 Injection of diagnostic agent into nerve of single lumbar paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of single lumbar paravertebral facet joint using imaging guidance; Injection of diagnostic agent into nerve of single sacral paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of single sacral paravertebral facet joint using imaging guidance; Injection of diagnostic agent into single lumbar paravertebral facet joint using fluoroscopic guidance;

Injection of diagnostic agent into single lumbar paravertebral facet joint using imaging guidance; Injection of diagnostic agent into single sacral paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into single sacral paravertebral facet joint using imaging guidance; Injection of therapeutic agent into nerve of single lumbar paravertebral facet joint using computed tomography (CT) guidance;

Injection of therapeutic agent into nerve of single sacral paravertebral facet joint using computed tomography (CT) guidance;

Injection of therapeutic agent into single lumbar paravertebral facet joint using computed tomography (CT) guidance;

Injection of therapeutic agent into single sacral paravertebral facet joint using computed tomography (CT) guidance.

#### 64494

Injection of diagnostic agent into nerve of second lumbar paravertebral facet joint using fluoroscopic guidance;

Injection of diagnostic agent into nerve of second lumbar paravertebral facet joint using imaging guidance;

Injection of diagnostic agent into nerve of second sacral paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of second sacral paravertebral facet joint using imaging guidance; Injection of diagnostic agent into second lumbar paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into second lumbar paravertebral facet joint using imaging guidance; Injection of diagnostic agent into second sacral paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into second sacral paravertebral facet joint using imaging guidance; Injection of therapeutic agent into nerve of second

lumbar paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into nerve of second sacral paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into second lumbar paravertebral facet joint using computed tomography (CT) guidance. Injection of diagnostic agent into nerve of third and any 64495 additional lumbar paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of third and any additional lumbar paravertebral facet joint using imaging guidance; Injection of diagnostic agent into nerve of third and any additional sacral paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into nerve of third and any additional sacral paravertebral facet joint using imaging guidance; Injection of diagnostic agent into third and any additional lumbar paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into third and any additional lumbar paravertebral facet joint using imaging guidance; Injection of diagnostic agent into third and any additional sacral paravertebral facet joint using fluoroscopic guidance; Injection of diagnostic agent into third and any additional sacral paravertebral facet joint using imaging guidance; Injection of therapeutic agent into nerve of third and any additional lumbar paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into nerve of third and any additional sacral paravertebral facet joint using

	computed tomography (CT) guidance; Injection of therapeutic agent into third and any additional lumbar paravertebral facet joint using computed tomography (CT) guidance; Injection of therapeutic agent into third and any additional sacral paravertebral facet joint using computed tomography (CT) guidance.	
64633	Destruction of single cervical paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of single cervical paravertebral facet joint nerve using neurolytic agent and using imaging guidance; Destruction of single thoracic paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of single thoracic paravertebral facet joint nerve using neurolytic agent and using imaging guidance; Destruction of single cervical paravertebral facet joint nerve using neurolytic agent and using computed tomography (CT) guidance; Destruction of single thoracic paravertebral facet joint nerve using neurolytic agent and using computed tomography (CT) guidance;	
64634	Destruction of each additional cervical paravertebral facet joint nerve using neurolytic agent and using computed tomography (CT) guidance; Destruction of each additional cervical paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of each additional cervical paravertebral facet joint nerve using neurolytic agent and using imaging guidance; Destruction of each additional thoracic paravertebral facet joint nerve using neurolytic agent and using computed tomography (CT) guidance;	

64635	Destruction of each additional thoracic paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of each additional thoracic paravertebral facet joint nerve using neurolytic agent and using imaging guidance.  Destruction of single lumbar paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of single lumbar paravertebral facet joint nerve using neurolytic agent and using imaging guidance; Destruction of single sacral paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of single sacral paravertebral facet joint nerve using neurolytic agent and using fluoroscopic guidance; Destruction of single sacral paravertebral facet joint nerve using neurolytic agent and using imaging guidance;	
64635	nerve using neurolytic agent and using fluoroscopic	
	Destruction of single lumbar paravertebral facet joint nerve using neurolytic agent and using imaging	
	nerve using neurolytic agent and using fluoroscopic	
	Destruction of single sacral paravertebral facet joint nerve using neurolytic agent and using imaging	
	Destruction of single lumbar paravertebral facet joint nerve using neurolytic agent and using computed tomography (CT) guidance;	
	Destruction of single sacral paravertebral facet joint nerve using neurolytic agent and using computed tomography (CT) guidance.	
64999	Unlisted procedure on nervous system	
0213Т	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level	
0214Т	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)	
0215T	Injection(s), diagnostic or therapeutic agent,	

	paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)	
0216T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level	
0217T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)	
0218T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)	

### **Medical Evidence**

Ashmore et al. (2022) performed a systematic review and meta-analysis on the use of fluroscopy to confirm needle placement when performing lumbar medical branch blocks (MBB) and facet joint injections (FJI). The authors note a high risk of incorrect needle placement using ultrasound guided MMB and FJI when fluroscopy or CT is used to confirm.<sup>2</sup>

Bodor et al. (2022) studied a total of 36 patients (60 cervical facet joints) with facet mediated pain. Ultrasound was used to guide the injections: C2-3 (22%), C3-4 (40%), C4-5 (33%) and C5-6 (5%). Overall the accuracy rate was high (92% to 98%) and patient outcomes were good.<sup>8</sup>

Kershen et al. (2018) performed a comparative study on the short- and long-term efficacy of intraarticular injections for lumbar pain. A total of 77 patients were examined; this includes 100 procedures with 205 total facet joints injected. Pain improvement scores were high immediately following injection and at one-week follow-up.<sup>9</sup>

Manchikanti et al. (2015) performed a systematic review to analyze the clinical efficacy of therapeutic facet joint interventions for individuals with chronic spinal pain. A literature review from 1966 through March 2015 yielded 21 randomized control trials (RCTs) that met inclusion criteria; a total of 5 observational studies were evaluated. Long-term efficacy is supported by Level II evidence of radiofrequency ablation (RFA) neurotomy and facet joint nerve blocks for the lumbar, cervical, and lumbar spine. Intraarticular injections had a Level III (lumbar) and Level IV (cervical and thoracic). The primary outcome measure was short term (6 months or less) and long term (6 months or more) pain relief. Secondary outcome measures included functional status improvement, psychological status, ability to return to work, and reducing opioid usage.<sup>10</sup>

#### National and Professional Organizations

The American Society of Interventional Pain Physicians (ASIPP) published a guideline on *Facet Joint Interventions in the Management of Chronic Spinal Pain*. The level of evidence is weak for the use of lumbar, cervical, and thoracic intraarticular facet joint injections.<sup>2</sup>

The American Society of Regional Anesthesia and Pain Medicine (ASRM) published a guideline on interventions for lumbar facet joint pain. Prior to RFA, MBB is recommended. Intraarticular injections are recommended for diagnostic and therapeutic purposes in certain patients. Therapeutic MBB and intraarticular injections are not recommended in most clinical scenarios (e.g., prolonged relief from prognostic blocks, contraindications to RFA).<sup>1</sup>

Guidelines are also available on interventions for cervical spine (facet) joint pain. The ASRM does not recommend the use of therapeutic intraarticular injections. A high technical failure rate is noted for intraarticular injections. In addition, MBB may be more clinically useful for RFA outcomes versus intraarticular injections.<sup>3</sup>

### References

- Cohen SP, Bhaskar A, Bhatia A, et al. Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. *Reg Anesth Pain Med.* 2020 Jun; 45(6):424–467. PMID: 32245841; PMCID: PMC7362874.
- 2. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive evidence-based guidelines for facet joint interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. *Pain Physician*. 2020 May; 23(3S):S1-S127. PMID: 32503359.
- 3. Hurley R, Adams MCB, Barad M, et al. Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group. *Reg Anesth Pain Med.* 2022 Jan; 47(1):3–59. doi: 10.1136/rapm-2021-103031. PMID: 34764220; PMCID: PMC8639967.
- Garcia D, Sousa-Pinto B, Akinduro OO, et al. SPECT-CT as a predictor of pain generators in patients undergoing intra-articular injections for chronic neck and back pain. World Neurosurg. 2022 Aug:164:e1243-e1250. doi: 10.1016/j.wneu.2022.06.013. PMID: 35691522. .
- 5. North American Spine Society (NASS). NASS coverage policy recommendations: Facet joint interventions. Published October 2016. Accessed July 1, 2024. https://www.spine.org/.
- Fletcher-Sandersjöö A, Edström E, Söderqvist AK, et al. Long-term pain relief following percutaneous steroid treatment of spinal synovial cysts: A population-based cohort study. *J Neurointerv Surg*. 2020 Sep;12(9):874-878. doi: 10.1136/neurintsurg-2020-015890. PMID: 32354843.
- 7. Ashmore ZM, Bies MM, Meiling JB, et al. Ultrasound-guided lumbar medial branch blocks and intraarticular facet joint injections: A systematic review and meta-analysis. *Pain Rep.* 2022 May 16;7(3):e1008. doi: 10.1097/PR9.000000000000000008. PMID: 35620250.
- 8. Bodor M, Murthy N, Uribe Y. Ultrasound-guided cervical facet joint injections. *Spine J.* 2022 Jun;22(6):983-992. doi: 10.1016/j.spinee.2022.01.011. PMID: 35093557.
- Kershen LM, Nacey NC, Patrie JT, et al. Fluoroscopically guided facet injections: Comparison of intra-articular and periarticular steroid and anesthetic injection on immediate and short-term pain relief. AJNR Am

- J Neuroradiol. 2018 Nov;39(11):2161-2165. PMID: 30287461; PMCID: PMC7655378.
- 10. Manchikanti L, Kaye AD, Boswell MV, et al. A systematic review and best evidence synthesis of the effectiveness of therapeutic facet joint interventions in managing chronic spinal pain. *Pain Physician*. 2015 Jul-Aug;18(4):E535-82. PMID: 26218948.

# Clinical Guideline Revision History/Information

Original Date: April 21, 2021				
Review History				
Version 2	12/1/2023			
Version 3	9/20/2024	Updated language regarding conservative treatment.		